Early vedolizumab as first treatment for colitis from immunotherapy
Treatments studied
Part of Digestive system clinical trials.
This trial tests if giving vedolizumab early can help control severe diarrhea and colon inflammation caused by immunotherapy (a type of cancer treatment). It may offer a new option for people who develop these side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You received immunotherapy for cancer within the last 8 weeks.
- You have been diagnosed with colitis (colon inflammation) linked to immunotherapy, confirmed by a scope or biopsy.
- Your diarrhea is grade 2 or 3 (moderate to severe, but not life-threatening).
- You have not needed strong steroids or other immune-suppressing drugs for colitis before.
- You are not currently hospitalized for this condition and can have treatment as an outpatient.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether vedolizumab, a drug that reduces gut inflammation, can prevent diarrhea caused by immunotherapy (a type of cancer treatment). It is for adults with advanced melanoma, lung, or kidney cancer who have a stool marker of inflammation early in treatment.
This study tests whether adding a special probiotic (VSL#3) to vedolizumab helps people with moderate ulcerative colitis more than vedolizumab alone. You may qualify if you are already planning to start vedolizumab and haven't responded well enough to other treatments.
This study tests the drug vedolizumab in adults with moderate to severe ulcerative colitis or Crohn's disease. It aims to see how well the medicine works in a community (non-hospital) setting.
This trial tests a new drug, OD-07656, followed by vedolizumab, in people with moderate to severe ulcerative colitis. It aims to see if this approach is safe and helps control symptoms when other treatments have not worked well.
This trial tests vedolizumab, a biologic medicine that reduces inflammation, in children and teenagers who have moderate to severe ulcerative colitis or Crohn's disease and have not responded well to other treatments.
This trial tests whether vedolizumab helps people with moderate-to-severe ulcerative colitis and what changes happen in the gut microbiome (the community of helpful bacteria in your intestines). You may be able to join if you’re an adult with ulcerative colitis who has not used vedolizumab before and haven’t taken certain gut-affecting medicines recently.
Hear when a new Immune Checkpoint Inhibitor-Related Colitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.